Abstract
This project studied the lowering blood lipids effect in atherosclerotic ApoE-deficient mice. Group A mice (n = 6), fed with a normal diet, served as the negative control. The experimental groups used mice fed with a high cholesterol diet (HCD) for eight weeks, and then selected for inclusion in the study on the basis of high blood lipid levels and the formation of atherosclerotic lesion plaque, which was indicated by an ultrasound biomicroscopy test. Eighteen mice met the selection criteria (atherosclerotic mice with high blood lipid levels) and these were randomly assigned into three groups B, C and D (n = 6). Group B fed with a HCD, served as the positive control. The intervention Group C was fed with HCD and Simvastatin. The intervention Group D was fed with a HCD and Hawthorn fruit compound (HFC includes Hawthorn and Kiwi fruit extract) for eight weeks. The results showed that after feeding on a HCD, Group B had significantly higher blood lipid levels compared to Group A and this confirmed the validity of Group A and Group B controls in this study. The results also showed that compared to Group B, in both Group C and D, there was a significant reduction in triglyceride and in the ratio between low-density lipoprotein cholesterol (LDL-C) and serum cholesterol. Moreover a reduction of LDL-C was evident in Group D, whereas a similar effect did not occur in Group C. The results indicate that HFC can be considered for the treatment of hyperlipidemia and prevention of atherosclerosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.